Faricimab versus High-Dose Aflibercept for the Treatment of Neovascular AMD and DME
Retina specialists evaluate the effectiveness of the two new therapies for neovascular AMD and DME by analyzing their respective clinical trial methodologies and outcomes.
To watch the video series component of this episode, click here.
0:00 Introduction
1:05 Overview of faricimab and high-dose aflibercept
3:48 clinical trials for faricimab and high-dose aflibercept
9:12 Comparing the matched dose phase results in clinical trials
12:30 Potential impacts of Ang-2 inhibition
14:40 Real-world experience with faricimab
22:00 Challenges with step therapy
24:00 Choosing between faricimab vs high-dose aflibercept
29:00 Perspectives on retreatment criteria in clinical trials
33:00 Label differences between faricimab and high-dose aflibercept
35:00 Final remarks
